In The Know-March 2021

March 2021

Pdf Summary

A series of studies and retrospective analyses in the field of gynecologic oncology have provided valuable insights into various aspects of cervical and ovarian cancer. Researchers have made progress in understanding the role of immune cells in ovarian cancer, finding that tumor-infiltrating γδ T cells have distinct characteristics and exhibit more innate-like functions compared to other T cells. This suggests that promoting γδ T cell responses may be a potential therapeutic option for ovarian cancer. In terms of ovarian cancer risk assessment, a study conducted in the Caribbean showed that 1 in 7 patients with breast or ovarian cancer carry pathogenic variants, highlighting the importance of genetic testing for inherited cancer predisposition in these populations. Additional research in the field has explored the effectiveness of integrative genomic profiling in advanced solid tumors, the clinical utility of olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer, and the use of point-of-care digital cytology with artificial intelligence for cervical cancer screening in resource-limited settings. Other studies have focused on the role of incomplete pregnancies in ovarian cancer risk, the prognostic value of biomarkers in ovarian cancer patients with endometriosis, and the accuracy and prognostic value of triaging HPV DNA-positive women using p16/ki67 and E6/E7 mRNA. These studies collectively contribute to expanding our understanding of ovarian and cervical cancer risk assessment, treatment strategies, and prognostic markers.

Keywords

gynecologic oncology

cervical cancer

ovarian cancer

immune cells

genetic testing

integrative genomic profiling

maintenance therapy

cervical cancer screening

incomplete pregnancies

prognostic markers